2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6251 Long-term access matters: Association between Medicaid expansion and survival in follicular lymphoma

Vanessa Velazquez, MD, Rafael Martin De Jesus Pichardo Rodriguez Sr, MD2, Qianqian Liu, PhD3, Joel Michalek, PhD4, Adolfo Diaz Duque, MD, MSc5
1 UT Health San Antonio, San Antonio, Texas, United States
2 Ricardo Palma University, Lima, Peru
3 UT Health San Antonio, San Antonio, Texas, United States
4 UT Health San Antonio, San Antonio, Texas, United States
5 UT Health San Antonio, San Antonio, Texas, United States

Background

Follicular lymphoma (FL) is an indolent lymphoma subtype with generally favorable survival outcomes. Despite this, disparities in access to care may influence long-term outcomes. Prior studies using national cancer datasets have demonstrated associations between Medicaid expansion under the Affordable Care Act (ACA) and improved mortality outcomes across several malignancies. The impact of Medicaid expansion on survival outcomes specifically among patients with follicular lymphoma remains unclear.

Methods

Adult patients diagnosed with FL between 2004 and 2023 were identified from the NCDB. States were categorized according to Medicaid expansion status and patients were stratified into pre-expansion (2004–2013) and post-expansion (2014–2023) cohorts. Baseline demographic, socioeconomic, and clinical characteristics were compared between groups. Overall survival was estimated using the Kaplan-Meier method with log-rank testing. Difference-in-differences (DiD) analysis was performed to determine whether Medicaid expansion was independently associated with changes in survival beyond nationwide temporal improvements.

Results

A total of 162,137 patients with FL were identified, including 75,775 (47%) diagnosed before Medicaid expansion and 86,362 (53%) after expansion. Overall, 124,578 (77%) patients resided in Medicaid expansion states and 37,559 (23%) in non-expansion states. Before 2014, 58,467 (77%) patients resided in expansion states versus 17,308 (23%) in non-expansion states; after 2014, 66,111 (77%) and 20,251 (23%), respectively (P=0.004).

Median age increased from 65 to 67 years following the ACA implementation (P<0.001). Female patients represented 52% of the pre-expansion cohort and 50% of the post-expansion cohort (P<0.001). Hispanic patients increased from 5% to 7% (P<0.001). Treatment at academic cancer programs increased from 51% to 54% (P<0.001). Government-sponsored insurance increased from 51% to 59%, whereas uninsured patients declined from 3% to 2% (P<0.001). Patients diagnosed after 2014 more frequently presented with stage III (27% vs. 23%) and stage IV disease (26% vs. 25%), while stage I disease decreased from 25% to 23% (P<0.001). Significant differences were also observed in household income, urban residence, educational attainment, and Charlson-Deyo comorbidity score (all P<0.001).

Overall survival was significantly higher among patients residing in Medicaid expansion states both before (log-rank P=2×10?4) and after (log-rank P<0.0001) ACA implementation. Estimated 2-, 5-, and 10-year OS in expansion states improved from 87.2%, 76.3%, and 60.5% before expansion to 88.9%, 77.2%, and 61.2% after expansion. Corresponding survival in non-expansion states improved from 86.2%, 75.1%, and 59.5% to 87.6%, 76.2%, and 59.2%, respectively. Difference-in-differences analysis demonstrated that Medicaid expansion was independently associated with improved long-term overall survival beyond secular improvements observed over time.

Conclusions

Patients with follicular lymphoma experienced significant improvements in overall survival during the ACA era. Survival remained consistently higher among patients residing in Medicaid expansion states both before and after implementation of Medicaid expansion, with the post-expansion period demonstrating a greater absolute survival advantage favoring expansion states. Difference-in-differences analysis suggests that expanded healthcare coverage was associated with improved long-term survival beyond secular advances in FL management. These findings support the potential role of Medicaid expansion in reducing disparities and improving outcomes among patients with follicular lymphoma.

Vanessa Velazquez, MD: No relevant conflicts of interest to declare.